Conditions: Hypertension
Keywords: Essential Hypertension Stage II
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 688
Healthy volunteers: no

Brief summary:
This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of 12 weeks.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg) intervention 2: Aliskiren (300 mg)
Intervention descriptions: intervention 1: During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week. intervention 2: During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.

Protocol document: